Description: Synairgen plc is a holding company. The Company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). The Company uses its human biology BioBank platform to discover and develop therapies for respiratory disease. Using the BioBank platform, it has developed a number of tissue models, which include In vitro and Ex vivo models. The Company's primary asset is AZD9412, which is an inhaled interferon beta (IFN-beta) therapy. AZD9412 is outlicensed to AstraZeneca for the clinical development and commercialization, and is in a confirmatory Phase II trial. Its drug programs include IFN-b (SNG001) for Asthma and COPD, and Lysyl oxidase-like protein 2 (LOXL2) inhibitors for IPF. The Company's subsidiary includes Synairgen Research Limited, which is engaged in the drug discovery and development.
Home Page: www.synairgen.com
SNG Technical Analysis
Mailpoint 810
Southampton,
SO16 6YD
United Kingdom
Phone:
44 23 8051 2800
Officers
| Name | Title |
|---|---|
| Mr. Richard Marsden | CEO, MD & Exec. Director |
| Prof. Stephen T. Holgate CBE, M.D. | Co-Founder, Non-Exec. Director & Member of Scientific Advisory Board |
| Mr. John Ward | CFO & Exec. Director |
| Dr. Phillip David Monk | Chairman of Scientific Advisory Board, Chief Scientific Officer & Exec. Director |
| Prof. Donna Davies | Co-Founder & Member of Scientific Advisory Board |
| Prof. Ratko Djukanovic | Co-Founder & Member of Scientific Advisory Board |
| Ms. Brooke S Clarke | Sr. VP & Head of Communications |
| Dr. Gareth E. Walters Ph.D. | Chief Regulatory Officer |
| Ms. Jody Brookes | Sr. VP & Head of Clinical Operations |
| Mr. Richard Hennings | Chief Commercial Officer |
Exchange: LSE
Country: UK : United Kingdom
Currency: Pence sterling (p)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.293 |
| Price-to-Sales TTM: | 759.0013 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 24 |